Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Colorectal Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Irinotecan 5Docetaxel 4Cisplatin 4Carboplatin 4Capecitabine 4Albumin-Bound Paclitaxel 4Paclitaxel 3Oxaliplatin 3Leucovorin 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3pazopanib 2palbociclib 2liposomal doxorubicin 2entrectinib 2alectinib 2Vinorelbine 2Trastuzumab 2Taxes 2Radiosurgery 2Oncolytic Virotherapy 2Observation 2Ipilimumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × umbralisib × Sarcoma × Clear all
NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡